Related Experiment Videos
Implications of peginterferon use in special populations infected with HCV
1Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0595, USA. Kenneth.Sherman@uc.edu
Insights
New hepatitis C virus (HCV) therapies are effective, but certain groups like those co-infected with HIV or with alcohol abuse history show lower response rates. Research identified host and viral factors contributing to these challenges.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Hepatitis C virus (HCV) infection treatments have advanced significantly, achieving sustained viral response in over half of patients.
- However, specific patient groups, including those with HCV/HIV co-infection, alcohol abuse, and African Americans with HCV, exhibit diminished treatment efficacy.
Purpose of the Study:
- To identify key factors influencing treatment response in special HCV-infected populations.
- To understand the complex interplay of host and viral characteristics affecting therapeutic outcomes.
Main Methods:
- Utilized viral kinetic modeling to analyze treatment response dynamics.
- Employed factor analysis to identify significant prognostic markers.
- Conducted laboratory evaluations of viral and host genomic factors.
Main Results:
- Identified a combination of poor prognostic host and viral factors in special populations.
- Peginterferons combined with ribavirin showed improved, but not complete, response rates in these groups.
- A response deficit persists compared to general populations in clinical trials.
Conclusions:
- Special populations with HCV exhibit reduced treatment response due to complex prognostic markers.
- While combination therapy offers benefits, it does not fully overcome the response deficit.
- Further research is needed to optimize HCV treatment strategies for these vulnerable groups.
Abstract:
Rapid progress in the treatment of hepatitis C virus (HCV) infection has led to highly successful therapies that lead to viral eradication and sustained viral response in more than 50% of patients. Despite these advances, certain identifiable subpopulations appear to have reduced rates of treatment response. These include patients co-infected with HCV/HIV, alcohol abusers, and African Americans infected with HCV. Using research tools including viral kinetic modeling, factor analysis, and laboratory evaluation of viral and host genomic characteristics, a number of key elements of response have been identified. Examination of special populations reveals that these groups comprise complex mixes of poor prognostic markers. These include both host and viral factors. Use of peginterferons with ribavirin improves response rates in these groups, but does not fully ameliorate the response deficit relative to patients enrolled in typical drug registration clinical trials.